Review articleMucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review
Introduction
Growing evidence indicates more aggressive regimens improve local tumor control and survival of patients with head and neck cancer [19]. Better treatment outcomes, however, have come at the expense of increased patient morbidity, notably an increase in severe (grades 3–4) mucositis that causes substantial pain, interferes with the patient's ability to chew and swallow, and worsens the patient's quality of life [44]. Patients report that mucositis is the most debilitating side effect of their head and neck cancer therapy (Alison Rose-Ped, unpublished observations, January 1999). Management of mucositis may require feeding tube placement, hospitalization, and intensive supportive care. We undertook a systematic review of the published literature in order to better characterize the incidence and clinical and economic consequences of mucositis in the head and neck cancer population. The results may inform the design of future intervention trials for mucositis. We limited our review to ‘acute’ mucositis which occurs during or shortly after active therapy, with no intention to capture the potential delayed consequences of mucositis.
Section snippets
Search strategy
The methods of systematic review used in this study have been well described elsewhere [12], [31], [39] and include the goal of minimizing bias in the collection and interpretation of clinical data. To further minimize the possibility of bias (or appearance thereof), a firm specializing in the conduct of systematic reviews (MetaWorks Inc.) was engaged to help design the study as well as to perform the data abstraction and analysis and write a summary of the results. Medline and Current Contents
Study characteristics
Thirty-three studies (n=6181) were accepted for inclusion in the analysis (Appendix). Table 1 summarizes the study characteristics. The majority of studies (21 studies, 64%) were performed in Europe. Fifteen of the 33 studies (45%) were considered adequately powered (Level of Evidence I) even though the median quality score in these studies was only 2 (scale 1–5, mean 2.7), implying questionable internal validity. Study duration was reported in 16 studies, ranging from 1.4 to 3 months.
Treatment characteristics
Treatment
Discussion
This systematic review confirms the high incidence of mucositis in patients receiving RT, with rates of 97% reported during RT-C, 100% during RT-AF, and 89% during chemoradiation therapy. The results underscore the impact of fractionation on the severity of mucositis: 56% of patients receiving RT-AF experienced grades 3–4 mucositis, compared with 34% of patients receiving RT-C and 43% of patients on RT+CT. These rates of severe mucositis are slightly higher than, but similar to, those recently
Acknowledgements
IntraBiotics Pharmaceuticals, Inc., Mountain View, CA, USA, supported this study.
References (47)
- et al.
Rules of evidence and clinical recommendations on the use of antithrombotic agents
Chest
(1992) - et al.
A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer
Radiother Oncol
(1997) - et al.
Results of a European randomized trial of Etanidazole combined with radiotherapy in head and neck carcinomas
Int J Radiat Oncol Biol Phys
(1997) - et al.
A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003
Int J Radiat Oncol Biol Phys
(2000) - et al.
Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial
Radiother Oncol
(1997) - et al.
Assessing the quality of reports of randomized clinical trials: is blinding necessary?
Control Clin Trials
(1996) - et al.
Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: a prospective randomized trial
Radiother Oncol
(1997) - et al.
Randomized clinical trial on accelerated 7 days per week fractionation in radiotherapy for head and neck cancer. Preliminary report on acute toxicity
Radiother Oncol
(1996) - et al.
A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85
Radiother Oncol
(1998) - et al.
Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative Group
Ann. Oncol
(1999)
The effect of pilocarpine and biperiden on salivary secretion during and after radiotherapy in head and neck cancer patients
Int J Radiat Oncol Biol Phys
Toxicity in head and neck cancer: a review of trends and issues
Int J Radiat Oncol Biol Phys
Concomitant radiotherapy with mitomycin C and bleomycin compared with radiotherapy alone in inoperable head and neck cancer: final report
Int J Radiat Oncol Biol Phys
A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: preliminary results
Head Neck
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099
J Clin Oncol
Low-energy He/Ne laser in the prevention of radiation-induced mucositis. A multicenter phase III randomized study in patients with head and neck cancer
Support Care Cancer
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer
N Engl J Med
Radiochemotherapy with amifostine cytoprotection for head and neck cancer
Support Care Cancer
Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma
J Natl Cancer Inst
Double blind randomized trial of sucralfate vs. placebo during radical radiotherapy for head and neck cancers
Head Neck
Sucralfate in the prevention of radiation-induced oral mucositis
J Clin Gastroenterol
Radiation therapy for early glottic carcinoma (T1N0M0). The final results of prospective randomized study concerning radiation field
Strahlenther Onkol
Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Asian-Oceanian Clinical Oncology Association Nasopharynx Cancer Study Group
Cancer
Cited by (925)
Efficacy of Prophylactic High-Dose Gabapentin and Venlafaxine on Reducing Oral Mucositis Pain Among Patients Treated With Chemoradiation for Head and Neck Cancer: A Single-Institution, Phase 2, Randomized Clinical Trial
2023, International Journal of Radiation Oncology Biology Physics